HighMark Wealth Management LLC - HTG MOLECULAR DIAGNOSTICS IN ownership

HTG MOLECULAR DIAGNOSTICS IN's ticker is HTGM and the CUSIP is 40434H104. A total of 29 filers reported holding HTG MOLECULAR DIAGNOSTICS IN in Q2 2020. The put-call ratio across all filers is - and the average weighting 0.1%.

Quarter-by-quarter ownership
HighMark Wealth Management LLC ownership history of HTG MOLECULAR DIAGNOSTICS IN
ValueSharesWeighting
Q3 2020$26,000
-27.8%
80,000
+60.0%
0.02%
-42.5%
Q2 2020$36,000
+176.9%
50,000
+25.0%
0.04%
+150.0%
Q1 2020$13,000
-90.3%
40,000
-79.2%
0.02%
-88.8%
Q4 2019$134,000192,0000.14%
Other shareholders
HTG MOLECULAR DIAGNOSTICS IN shareholders Q2 2020
NameSharesValueWeighting ↓
PERKINS CAPITAL MANAGEMENT INC 2,426,300$802,0000.74%
Cowen Prime Services LLC 1,411,500$466,0000.23%
GSA CAPITAL PARTNERS LLP 1,205,873$398,0000.07%
Nantahala Capital Management 5,113,958$1,690,0000.05%
HighMark Wealth Management LLC 80,000$26,0000.02%
Kalos Management, Inc. 72,858$24,0000.01%
Qube Research & Technologies Ltd 585,187$193,0000.00%
WINTON GROUP Ltd 190,146$63,0000.00%
Ironwood Financial, llc 1,571$1,0000.00%
Virtu Financial LLC 12,049$4,0000.00%
View complete list of HTG MOLECULAR DIAGNOSTICS IN shareholders